Population Health: cancer prevention and early detection
Dr Rebecca Beeken – Yorkshire Cancer Research University Academic Fellow, University of Leeds
Professor John Saxton – Professor in Clinical Exercise Physiology, Northumbria University
Professor Annie Anderson – Professor of Public Health Nutrition, Dundee Centre for Research into Cancer Prevention and Screening
Professor Janet Cade – Professor of Nutritional Epidemiology and Public Health, University of Leeds
Professor Amanda Cross – Professor in Cancer Epidemiology, Imperial College London
Dr Fiona Kennedy – Research Fellow, University of Leeds
Professor Richard Martin – Professor of Clinical Epidemiology, University of Bristol, Bristol BRC
Dr Giota Mitrou – Director of Research Funding & Science External Relations, WCRF
Dr Aurora Perez-Cornago – Associate Professor of Nutritional Epidemiology & Cancer Research UK Population Health Research Fellow, University of Oxford
Professor Elio Riboli – Chair in Cancer Epidemiology and Prevention, Imperial College London
Professor Andrew Renehan – Professor of Cancer Studies and Surgery, University of Manchester; Honorary Consultant Colorectal Surgeon
Dr Julie Walabyeki – Research Fellow, Hull and York Medical School
Population health research work stream - Phase III research strategy
Work Stream Publications
Cancer prevention through weight control – where are we in 2020?
Cancer survivorship and excess body fatness – where are we in 2020?
On Saturday 27th April 2019, the NIHR Cancer and Nutrition Collaboration held a satellite to the European Congress on Obesity which set out to explore issues about future research on obesity and cancer occurrence (primary prevention) and recurrence (cancer survivorship) with a focus on intervention trials. It was hosted by The Centre for Research Into cancer Prevention and Screening (CRIPS), University of Dundee and chaired by Prof Bob Steele (Dundee) and Prof Elio Riboli (Imperial College) aided by Professor Andrew Renehan (University of Manchester).
Key issues that arose from discussions:
- Can we realistically consider weight loss trials for primary and or secondary prevention?
- How can we best explore causal association and reversibility?
- Who should our target population include and exclude?
- Can we develop and deliver the ‘right’ intervention?
- What is the optimal timing for intervention and length of duration?
- What are the most clinically relevant disease outcomes that can be realistically measured?
The report of the meeting is available here: Action on weight management in cancer – meeting report
The presentations of the speakers are available here:
F Sniehotta L Rehackova part 1
F Sniehotta L Rehackova part 2